EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study

Anthony Buisson, Mélanie Serrero, Romain Altwegg, Thomas Guilmoteau, Guillaume Bouguen, Maria Nachury, Aurélien Amiot, Lucine Vuitton, Xavier Treton, Ludovic Caillo, Bruno Pereira, Mathurin Fumery

Clinical Gastroenterology and Hepatology · 2026-04 · 24 (4) · 1141-1150

DOI: 10.1016/j.cgh.2025.07.044 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-04. Verfasst von Anthony Buisson und 11 weiteren Autor:innen. Beteiligte Einrichtung: Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France; Université Clermont A…. Hauptthemen laut MEDLINE: Ustekinumab, Piperidines, Pyrimidines, Colitis, Ulcerative. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Centre Hospitalier Universitaire de Clermont-Ferrand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: We compared the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis (UC) previously exposed to at least one anti-tumor necrosis factor (TNF) agent. METHODS: In this multicenter real-world evidence study, we consecutively included patients with UC ≥18 years old, previously exposed to anti-TNF therapy, with partial Mayo score >2 and, starting tofacitinib or ustekinumab. All the comparisons were performed using propensity score analyses. RESULTS: Overall, 124 and 165 patients were included in the tofacitinib and ustekinumab groups, respectively. Symptomatic remission, off corticosteroids (partial Mayo score ≤2) was achieved at week 16 in 37.8% and 35.8%, among the tofacitinib and ustekinumab groups, respectively (adjusted odds ratio [OR], 1.09; 95% confidence interval [CI], 0.60-2.00; P = .75), with higher tofacitinib effectiveness in patients with prior exposure to ≥3 biologics (46.7% vs 23.1%; adjusted OR, 2.92; 95% CI, 1.02-8.39; P = .047). Primary failure to any biologic (OR, 2.88; 95% CI, 1.20-6.98) and prior exposure to ≥3 advanced therapies (OR, 2.45; 95% CI, 1.03-5.82), but not disease severity, were associated with ustekinumab failure. We did not find any significant difference between tofacitinib and ustekinumab regarding clinical remission per modified Mayo score (17.0% vs 11.7%; adjusted OR, 1.55; 95% CI, 0.65-3.68; P = .32) and histological and endoscopic improvement (4.4% vs 7.8%; adjusted OR, 0.54; 95% CI, 0.16-1.86; P = .32). After a median follow-up of 11.8 months (interquartile range, 6.1-20.5 months), we did not observe any difference regarding the risk of UC relapse-related drug discontinuation (adjusted hazard ratio, 1.44; 95% CI, 0.94-2.21; P = .10), and the risk of secondary loss of response among patients achieving CFREM at week 16 (adjusted hazard ratio, 1.88; 95% CI, 0.57-6.19; P = .30). CONCLUSIONS: Tofacitinib and ustekinumab are similarly effective to induce and maintain corticosteroid-free remission after anti-TNF failure in UC. However, tofacitinib could be favored in case of multiple therapeutic failures (≥3 biologics) and primary failure to any biologic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabPiperidinesPyrimidinesColitis, UlcerativeHumansMaleFemaleMiddle AgedAdultTreatment OutcomeAged

Stichwörter der Autor:innen

Inflammatory Bowel DiseaseJAK InhibitorsTofacitinibUlcerative ColitisUstekinumab

Substanzen

tofacitinibUstekinumabPiperidinesPyrimidines

Autor:innen und Institutionen

  • Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France; Université Clermont Auvergne, Inserm U1071, M2iSH, USC-INRA 2018, Clermont-Ferrand, France.…
  • Department of Gastroenterology, University Hospital of Marseille Nord, Aix-Marseille, Marseille University, Marseille, France.
  • Department of Hepatogastroenterology, CHU St Eloi Montpellier, Montpellier, France.
  • Université Clermont Auvergne, Inserm, 3iHP, CHU Clermont-Ferrand, Service d'Hépato-Gastroentérologie, Clermont-Ferrand, France.
  • CHU Rennes, Université Rennes, INSERM, CIC1414, Institut NUMECAN (Nutrition Metabolism and Cancer), Rennes, France.
  • Université Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.

Förderung

  • Centre Hospitalier Universitaire de Clermont-Ferrand

Zitieren

APA

Buisson, A., Serrero, M., Altwegg, R., Guilmoteau, T., Bouguen, G., Nachury, M., Amiot, A., Vuitton, L., Treton, X., Caillo, L., Pereira, B., & Fumery, M. (2026). Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study. Clinical Gastroenterology and Hepatology, 24(4), 1141-1150. https://doi.org/10.1016/j.cgh.2025.07.044

Vancouver

Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, et al. Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study. Clinical Gastroenterology and Hepatology. 2026;24(4):1141-1150. doi:10.1016/j.cgh.2025.07.044

BibTeX
@article{Buisson2026,
  author = {Buisson, Anthony and Serrero, Mélanie and Altwegg, Romain and Guilmoteau, Thomas and Bouguen, Guillaume and Nachury, Maria and Amiot, Aurélien and Vuitton, Lucine and Treton, Xavier and Caillo, Ludovic and Pereira, Bruno and Fumery, Mathurin},
  title = {Real-World Comparison of the Effectiveness of Tofacitinib and Ustekinumab in Patients With Ulcerative Colitis: The TORUS Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {1141--1150},
  doi = {10.1016/j.cgh.2025.07.044}
}
Kostenlos starten →